PPARγ gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus
Open Access
- 24 March 2010
- journal article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 9 (1), 13
- https://doi.org/10.1186/1475-2840-9-13
Abstract
Background Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor, which regulates gene expression of the key proteins involved in lipid metabolism, vascular inflammation, and proliferation. PPARγ may contribute to attenuating atherogenesis and postangioplasty restenosis. PPARγ C161→T substitution is associated with a reduced risk of coronary artery disease (CAD). Whether or not the gene substitution alters the risk of CAD in type 2 diabetes mellitus (T2DM) patients remains unclear. Methods A total of 556 unrelated subjects from a Chinese Han population, including 89 healthy subjects, 78 CAD patients, 86 T2DM patients, and 303 CAD combined with T2DM patients, were recruited to enroll in this study. PPARγC161→T gene polymorphism was determined by polymerase chain reaction and restriction fragment length polymorphisms. Plasma levels of lipoproteins, apolipoproteins, glucose, and insulin were measured by ELISA or radioimmunoassay (RIA). The coronary artery lesions were evaluated by coronary angiography. Results The frequency of the 161T allele in CAD, T2DM, and CAD combined with T2DM patients was similar to that observed in the healthy control group. However, in CAD combined with T2DM patients, the group with angiographically documented moderate stenoses had a higher frequency of the 161T allele in comparison to the group with severe stenoses (P < 0.05). Moreover, in CAD with T2DM patients, the triglyceride levels and apoB in CC homozygote carriers were significantly higher than those in "T" allele carriers. Conclusions PPARγC161→T genotypes weren't significantly associated with the risk of CAD, but were markedly correlated with severity of disease vessels in patients with CAD and T2DM. Furthermore, PPARγC161→T substitution was associated with an altered adipose, but not glucose metabolism. These results indicate that the PPARγ C161→T polymorphism may reduce the risk of severe atherogenesis by modulation of adipose metabolism, especially triglycerides and apoB, in Chinese patients with CAD and T2DM.Keywords
This publication has 32 references indexed in Scilit:
- Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndromeDiabetes, Obesity and Metabolism, 2009
- Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator‐activated receptor gammaEuropean Journal of Clinical Investigation, 2008
- PPARγ gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expressionAmerican Heart Journal, 2007
- Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis StudyCirculation, 2004
- TracheomalaciaPaediatric Respiratory Reviews, 2004
- Epidemiology of DiabetesThe Journal of Clinical Pharmacology, 2004
- PPARα and PPARγ activators suppress the monocyte-macrophage apoB-48 receptorJournal of Lipid Research, 2003
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.JCI Insight, 1997
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990